Singapore - English - HSA (Health Sciences Authority)

bayer (south east asia) pte ltd - (tablet core, product) drospirenone; (tablet core, product) ethinylestradiol betadex clathrate - tablet, film coated - 3.000 mg - (tablet core, product) drospirenone 3.000 mg; (tablet core, product) ethinylestradiol betadex clathrate 0.020 mg

Australia - English - Department of Health (Therapeutic Goods Administration)

sun pharma anz pty ltd - methylprednisolone, quantity: 4 mg - tablet - excipient ingredients: gelatin; maize starch; magnesium stearate; purified talc; lactose monohydrate - yonsa mpred is indicated for the treatment of patients with: newly diagnosed high-risk metastatic hormone sensitive prostate cancer (mhspc) in combination with androgen deprivation therapy (adt), or; patients with metastatic advanced prostate cancer (castration resistant prostate cancer, mcrpc) who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy (adt) or; patients with mcrpc who have received prior chemotherapy containing a taxane.

United States - English - NLM (National Library of Medicine)

celltech pharmaceuticals, inc. - metolazone (unii: tz7v40x7vx) (metolazone - unii:tz7v40x7vx) - tablet - 500 ug - mykrox tablets are indicated for the treatment of hypertension, alone or in combination with other antihypertensive drugs of a different class. mykrox tablets have not been evaluated for the treatment of congestive heart failure or fluid retention due to renal or hepatic disease and the correct dosage for these conditions and other edema states has not been established. since a safe and effective diuretic dose has not been established, mykrox tablets should not be used when diuresis is desired. the routine use of diuretics in an otherwise healthy woman is inappropriate and exposes mother and fetus to unnecessary hazard. diuretics do not prevent development of toxemia of pregnancy, and there is no evidence that they are useful in the treatment of developed toxemia (see precautions). edema during pregnancy may arise from pathologic causes or from the physiologic and mechanical consequences of pregnancy. mykrox is not indicated for the treatment of edema in pregnancy. dependent edema in pregnancy resulting

Australia - English - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - olanzapine, quantity: 15 mg - tablet, film coated - excipient ingredients: hypromellose; microcrystalline cellulose; magnesium stearate; lactose monohydrate; hyprolose; crospovidone; titanium dioxide; polysorbate 80; macrogol 400; indigo carmine aluminium lake - olanzapine tablets are indicated for the treatment of schizophrenia and related psychoses.,olanzapine tablets alone or in combination with lithium or valproate is indicated for the short-term treatment of acute manic episodes associated with bipolar i disorder.,olanzapine tablets are also indicated for preventing recurrence of manic, mixed or depressive episodes in bipolar i disorder.

Australia - English - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - olanzapine, quantity: 5 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; crospovidone; magnesium stearate; hypromellose; lactose monohydrate; hyprolose; titanium dioxide; polysorbate 80; macrogol 400 - olanzapine tablets are indicated for the treatment of schizophrenia and related psychoses. ,olanzapine tablets alone or in combination with lithium or valproate is indicated for the short-term treatment of acute manic episodes associated with bipolar i disorder. ,olanzapine tablets are also indicated for preventing recurrence of manic, mixed or depressive episodes in bipolar i disorder.

Australia - English - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - olanzapine, quantity: 15 mg - tablet, film coated - excipient ingredients: hyprolose; crospovidone; magnesium stearate; microcrystalline cellulose; lactose monohydrate; hypromellose; titanium dioxide; polysorbate 80; macrogol 400; indigo carmine aluminium lake - olanzapine tablets are indicated for the treatment of schizophrenia and related psychoses. ,olanzapine tablets alone or in combination with lithium or valproate is indicated for the short-term treatment of acute manic episodes associated with bipolar i disorder. ,olanzapine tablets are also indicated for preventing recurrence of manic, mixed or depressive episodes in bipolar i disorder.

Australia - English - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - olanzapine, quantity: 10 mg - tablet, film coated - excipient ingredients: hypromellose; crospovidone; microcrystalline cellulose; lactose monohydrate; magnesium stearate; hyprolose; titanium dioxide; polysorbate 80; macrogol 400 - olanzapine tablets are indicated for the treatment of schizophrenia and related psychoses. ,olanzapine tablets alone or in combination with lithium or valproate is indicated for the short-term treatment of acute manic episodes associated with bipolar i disorder. ,olanzapine tablets are also indicated for preventing recurrence of manic, mixed or depressive episodes in bipolar i disorder.

Australia - English - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - rosuvastatin calcium, quantity: 41.6 mg (equivalent: rosuvastatin, qty 40 mg) - tablet, film coated - excipient ingredients: lactose monohydrate; magnesium stearate; crospovidone; light magnesium oxide; microcrystalline cellulose; titanium dioxide; hypromellose; triacetin; iron oxide red - primary hypercholesterolaemia,pharmacor ezetimibe rosuvastatin composite pack is indicated as adjunctive therapy to diet in patients with primary (heterozygous familial and non-familial) hypercholesterolaemia where use of a combination product is appropriate in those patients:,? not appropriately controlled with rosuvastatin or ezetimibe alone; or,? already treated with rosuvastatin and ezetimibe,homozygous familial hypercholesterolaemia (hofh),pharmacor ezetimibe rosuvastatin composite pack is indicated for patients with hofh. patients may also receive adjunctive treatments (e.g., ldl apheresis).

Australia - English - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - rosuvastatin calcium, quantity: 20.8 mg (equivalent: rosuvastatin, qty 20 mg) - tablet, film coated - excipient ingredients: lactose monohydrate; light magnesium oxide; microcrystalline cellulose; crospovidone; magnesium stearate; titanium dioxide; hypromellose; triacetin; iron oxide red - primary hypercholesterolaemia,pharmacor ezetimibe rosuvastatin composite pack is indicated as adjunctive therapy to diet in patients with primary (heterozygous familial and non-familial) hypercholesterolaemia where use of a combination product is appropriate in those patients:,? not appropriately controlled with rosuvastatin or ezetimibe alone; or,? already treated with rosuvastatin and ezetimibe,homozygous familial hypercholesterolaemia (hofh),pharmacor ezetimibe rosuvastatin composite pack is indicated for patients with hofh. patients may also receive adjunctive treatments (e.g., ldl apheresis).

Australia - English - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - rosuvastatin calcium, quantity: 10.4 mg (equivalent: rosuvastatin, qty 10 mg) - tablet - excipient ingredients: magnesium stearate; microcrystalline cellulose; lactose monohydrate; light magnesium oxide; crospovidone; titanium dioxide; hypromellose; triacetin; iron oxide red - primary hypercholesterolaemiapharmacor ezetimibe rosuvastatin composite pack is indicated as adjunctive therapy to diet in patients with primary (heterozygous familial and non-familial) hypercholesterolaemia where use of a combination product is appropriate in those patients:,? not appropriately controlled with rosuvastatin or ezetimibe alone; or,? already treated with rosuvastatin and ezetimibe,homozygous familial hypercholesterolaemia (hofh),pharmacor ezetimibe rosuvastatin composite pack is indicated for patients with hofh. patients may also receive adjunctive treatments (e.g., ldl apheresis).